In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position on the safety or efficacy of the product or therapy described.
On June 12, 2026, the Food and Drug Administration approved belzutifan (Welireg, Merck & Co., Inc.) in combination with pembrolizumab (Keytruda, Merck & Co., Inc.) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck & Co., Inc.) for the adjuvant treatment of adults with renal cell carcinoma with a clear cell component (ccRCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.
Full prescribing information for Welireg, Keytruda, and Keytruda Qlex will be posted on Drugs@FDA.
Efficacy and Safety
Efficacy was evaluated in LITESPARK-022 (NCT05239728), a multicenter, double-blind, randomized trial in 1,841 patients with prior nephrectomy for ccRCC who were at intermediate-high or high risk of recurrence, or who had resected metastases with no evidence of disease. Patients were randomized (1:1) to receive belzutifan in combination with pembrolizumab as adjuvant therapy or placebo in combination with pembrolizumab until disease recurrence or unacceptable toxicity or for up to 54 weeks of belzutifan or 12 months of pembrolizumab.
The major efficacy outcome measure was investigator-assessed disease-free survival (DFS), defined as time to recurrence, metastasis, or death. A statistically significant improvement in DFS was demonstrated at a prespecified interim analysis with 186 events in the belzutifan with pembrolizumab arm and 246 events in the placebo with pembrolizumab arm (hazard ratio 0.72 [95% CI: 0.59, 0.87]; p-value 0.0003). Median DFS was not reached in either arm. Overall survival data were not mature at the protocol pre-specified interim analysis.
The belzutifan prescribing information includes a boxed warning for embryo-fetal toxicity and warnings and precautions for anemia and hypoxia. The pembrolizumab prescribing information includes warnings and precautions for immune-mediated adverse reactions, infusion-related reactions, complications of allogeneic hematopoietic stem cell transplantation, and embryo-fetal toxicity.
Recommended Dosage
The recommended belzutifan dose is 120 mg orally once daily in combination with pembrolizumab or pembrolizumab and berahyaluronidase-pmph alfa until disease recurrence or unacceptable toxicity, or for up to 54 weeks.
The recommended pembrolizumab dose is 200 mg intravenously every three weeks or 400 mg every six weeks in combination with belzutifan 120 mg orally once daily until disease recurrence, unacceptable toxicity, or for up to 12 months. The recommended pembrolizumab and berahyaluronidase alfa-pmph dose is 395 mg/4,800 units subcutaneously every three weeks or 790 mg/9,600 units every six weeks in combination with belzutifan 120 mg orally once daily until disease recurrence, unacceptable toxicity, or for up to 12 months.
This review was conducted under Project Orbis, an initiative of the FDA Oncology Center of Excellence. Project Orbis provides a framework for concurrent submission and review of oncology drugs among international partners. For this review, FDA collaborated with the Australian Therapeutic Goods Administration (TGA) and Health Canada. The application reviews are ongoing at the other regulatory agencies.
This review used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA’s assessment.
This application was granted priority review. A description of FDA expedited programs is in the Guidance for Industry: Expedited Programs for Serious Conditions-Drugs and Biologics.
Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System or by calling 1-800-FDA-1088.
For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact OCE’s Project Facilitate at 240-402-0004 or email OncProjectFacilitate@fda.hhs.gov.